Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 63008G203 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Tang Capital Management LLC
13G
|
9.1% |
8/21/2026
Event 8/19/2026
|
|
| Tang Capital Management, LLC | 9.1% | ||
| Kevin Tang | 9.1% | ||
| Tang Capital Partners, LP | 2.1% | ||
| Tang Capital Partners International, LP | 2.8% | ||
| Tang Capital Partners III, Inc | 2.1% | ||
| Tang Capital Partners IV, Inc | 2.1% | ||
|
Tang Capital Management LLC
13D/A
Amendment 1
|
7.9% |
7/27/2026
Event 7/23/2026
|
|
| Tang Capital Management, LLC | 7.9% | ||
| Kevin Tang | 7.9% | ||
| Tang Capital Partners, LP | 1.8% | ||
| Tang Capital Partners International, LP | 2.5% | ||
| Tang Capital Partners III, Inc | 1.8% | ||
| Tang Capital Partners IV, Inc | 1.8% | ||
| Concentra Biosciences, LLC | 0% | ||
| Oramed Pharmaceuticals Inc. 13D/A Amendment 3 | 3.3% |
7/22/2026
Event 7/20/2026
|
|
|
Murchinson Ltd.
13D/A
Amendment 18
|
8.1% |
7/20/2026
Event 7/17/2026
|
|
| Murchinson Ltd. | 8.1% | ||
| Nomis Bay Ltd. | 2.4% | ||
| BPY Ltd. | 1.6% | ||
| EOM Management Ltd. | 4.1% | ||
| James Keyes | 4.1% | ||
| Jason Jagessar | 4.1% | ||
| Chaja Carlebach | 4.1% | ||
| Clarendon Hugh Masters | 4.1% | ||
| Marc J. Bistricer | 8.1% | ||
|
Tang Capital Management LLC
13D
|
6.8% |
6/30/2026
Event 6/24/2026
|
|
| Tang Capital Management, LLC | 6.8% | ||
| Kevin Tang | 6.8% | ||
| Tang Capital Partners, LP | 1.6% | ||
| Tang Capital Partners International, LP | 2.0% | ||
| Tang Capital Partners III, Inc | 1.6% | ||
| Tang Capital Partners IV, Inc | 1.6% | ||
| Concentra Biosciences, LLC | 0% | ||
|
Murchinson Ltd.
13D/A
Amendment 17
|
9.6% |
6/23/2026
Event 6/22/2026
|
|
| Murchinson Ltd. | 9.6% | ||
| Nomis Bay Ltd. | 2.9% | ||
| BPY Ltd. | 1.9% | ||
| EOM Management Ltd. | 4.8% | ||
| James Keyes | 4.8% | ||
| Jason Jagessar | 4.8% | ||
| Chaja Carlebach | 4.8% | ||
| Clarendon Hugh Masters | 4.8% | ||
| Marc J. Bistricer | 9.6% | ||
| Oramed Pharmaceuticals Inc. 13D/A Amendment 2 | 7.2% |
6/17/2026
Event 6/15/2026
|
|
|
Murchinson Ltd.
13D/A
Amendment 16
|
7.4% |
5/21/2026
Event 5/19/2026
|
|
| Murchinson Ltd. | 7.4% | ||
| Nomis Bay Ltd. | 2.2% | ||
| BPY Ltd. | 1.5% | ||
| EOM Management Ltd. | 3.7% | ||
| James Keyes | 3.7% | ||
| Jason Jagessar | 3.7% | ||
| Chaja Carlebach | 3.7% | ||
| Marc J. Bistricer | 7.4% | ||
| Oramed Pharmaceuticals Inc. 13D/A Amendment 1 | 5.2% |
2/19/2026
Event 2/17/2026
|
|
|
Oramed Pharmaceuticals Inc.
13D
|
5.0% |
1/29/2026
Event 1/29/2026
|
|
| Oramed Pharmaceuticals Inc. | 5.0% | ||
| Nadav Kidron | 5.0% | ||
|
Anson Funds Management LP
13D/A
Amendment 6
|
4.2% |
7/14/2025
Event 7/11/2025
|
|
| Anson Funds Management LP | 4.2% | ||
| Anson Management GP LLC | 4.2% | ||
| Tony Moore | 4.2% | ||
| Anson Advisors Inc. | 4.2% | ||
| Amin Nathoo | 4.2% | ||
| Moez Kassam | 4.2% | ||
|
Anson Funds Management LP
13D/A
Amendment 5
|
7.5% |
7/3/2025
Event 6/26/2025
|
|
| Anson Funds Management LP | 7.5% | ||
| Anson Management GP LLC | 7.5% | ||
| Tony Moore | 7.5% | ||
| Anson Advisors Inc. | 7.5% | ||
| Amin Nathoo | 7.5% | ||
| Moez Kassam | 7.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 8 | 84.2 k | $132 k |
| 2026 Q2 | 113 | 67.2 M | $97.4 M |
| 2026 Q1 | 114 | 59.1 M | $100 M |
| 2025 Q4 | 126 | 70.0 M | $108 M |
| 2025 Q3 | 129 | 71.8 M | $113 M |
| 2025 Q2 | 140 | 77.5 M | $126 M |
| 2025 Q1 | 153 | 74.3 M | $118 M |
| 2024 Q4 | 160 | 76.9 M | $191 M |
| 2024 Q3 | 151 | 70.8 M | $173 M |
| 2024 Q2 | 144 | 74.0 M | $163 M |
| 2024 Q1 | 142 | 76.7 M | $213 M |
| 2023 Q4 | 153 | 73.2 M | $176 M |
| 2023 Q3 | 150 | 69.7 M | $189 M |
| 2023 Q2 | 150 | 74.7 M | $216 M |
| 2023 Q1 | 155 | 89.1 M | $257 M |
| 2022 Q4 | 166 | 71.7 M | $1.09 B |
| 2022 Q3 | 170 | 60.7 M | $145 M |
| 2022 Q2 | 172 | 64.9 M | $201 M |
| 2022 Q1 | 179 | 57.6 M | $205 M |
| 2021 Q4 | 181 | 54.4 M | $208 M |
| 2021 Q3 | 173 | 47.9 M | $271 M |
| 2021 Q2 | 185 | 52.3 M | $431 M |
| 2021 Q1 | 170 | 43.2 M | $370 M |
| 2020 Q4 | 117 | 25.4 M | $232 M |
| 2020 Q3 | 36 | 1.47 M | $4.21 M |
| 2020 Q2 | 31 | 1.28 M | $2.81 M |
| 2020 Q1 | 12 | 365 k | $349 k |
| 2019 Q4 | 11 | 110 k | $281 k |
| 2019 Q3 | 2 | 743 k | $305 k |
| 2019 Q2 | 1 | 800 | $7.00 k |
| 2019 Q1 | 1 | 800 | $7.00 k |